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INTRODUCTION

DIHYDROWRIMIDINE DEHYDROGENASE
(DPD, EC 1.3.1.2) is the initial and rate-limiting enzyme in the catabolism of the pyrimidine bases and it catalyses the reduction of thymine and uracil to 5,6-dihydrothymine and 5,6_dihydrouracil, respectively. In children, the deficiency of DPD is often accompanied by a neurological disorder but a considerable variation in the clinical presentation among these patients has been reported [l] . In these patients, a large accumulation of uracil and thymine has been detected in urine, blood and in cerebrospinal fluid [l-3] . Recently, we provided the first evidence at the molecular level that the mRNA of a patient with a deficiency of dihydropyrimidine dehydrogenase lacked a segment of 165 nucleotides that results from exon skipping with the splicing error being caused by a point mutation in an invariant GT splice donor sequence in the intron downstream of the skipped exon [4-61. DPD is also responsible for the breakdown of the widely used antineoplastic agent Sfluorouracil (5-FU), thereby limiting the efficacy of the therapy. 5-FU is one of the few drugs that shows some antitumour activity against various otherwise untreatable tumours including carcinomas of the gastrointestinal tract, breast, ovary and skin. Although the cytotoxic effects of 5-FU are probably directly mediated by the anabolic pathways, the catabolic route plays a significant role since more than 80% of the administered 5-FU is catabolised by DPD [7] . Indeed, inhibitors of DPD have been shown to potentiate the effect of 5-FU in vitro and in vivo [8-lo] .
The important role of DPD in chemotherapy with 5-FU has been shown in cancer patients with a complete or nearcomplete deficiency of this enzyme. These patients suffered from severe (neuro)toxicity, including death, following 5-FU chemotherapy [l l-191 , including 2 cancer patients with a complete deficiency of DPD [12, 131, 3 patients with a suspected deficiency of DPD [ 11,151 and 13 patients with a very low activity of DPD [14, . A clinical pharmacological study of one of these patients with a complete deficiency of DPD demonstrated minimal catabolism of 5-FU with a lofold longer 5-FU half-life compared with patients with a normal activity of DPD [ 121.
It has been suggested that patients suffering from 5-FU toxicities due to a low activity of DPD are genotypically heterozygous for a mutant allele of the gene encoding DPD [20] . Furthermore, the frequency of heterozygotes in the normal population has been estimated to be as high as 3% [20-231. So far, heterozygosity for a mutated DPD allele has only been shown in 1 cancer patient [24] . In this paper, we demonstrate that a patient experiencing severe toxicity following 5-FU chemotherapy proved to be heterozygous for a G-+A point mutation in an invariant GT splice donor sequence, leading to faulty splicing. Furthermore, the G-A point mutation has also been found in 8 out of 11 other patients suffering from a complete DPD deficiency.
MATERIALS AND METHODS
Materials
AmpliTaq Taq polymerase was supplied by Perk&Elmer (San Jose, California, U.S.A.). A Qiaquickspin PCR purification kit was obtained from Qiagen (Hilden, Germany). Dye-primer cycle-sequence-ready reaction kits were obtained from Applied Biosystems (San Jose, California, U.S.A.). Oligonucleotides were synthesised on a Millipore Expedite oligonucleotide synthesiser. HAM-F1 0 culture medium, fetal calf serum and newborn calf serum were obtained from Gibco Laboratories (Paisley, Scotland). [2-14C]Thymine was obtained from Biotrend GmbH (Koln, Germany). Lymphopaque was obtained from Nyegaard & Co (Oslo, Norway). LeucoSep tubes were supplied by Greiner (Frickenhausen, Germany). All other chemicals were of analytical grade.
Culture conditions of the human jibroblasts
Fibroblasts were cultured from skin biopsies obtained from controls (healthy volunteers and patients admitted to our hospital with clinical and biochemical findings not indicative of inborn errors in the purine and pyrimidine metabolism, mitochondrial oxidative phosphotylation or disorders in the urea cycle), patients with a DPD deficiency and obligate heterozygotes (e.g. parents of the affected family member).
Biopsies were incubated at 37°C in HAM-F10 medium supplemented with 20mM HEPES and 20% (v/v) fetal calf serum in 25 cm2 cell-culture flasks until an adequate number of proliferating cells was obtained. Subsequently, the cells were harvested with 0.25% (w/v) trypsin and distributed over two 75 cm* flasks. These cells were cultured in HAM-F10 medium supplemented with 20 mM HEPES and 15% (v/v) newborn calf serum. Monolayers of fibroblasts were grown to confluency and harvested with 0.25% (w/v) trypsin. After washing the cells twice with PBS (9.2mM NasHPOd, 1.3mM NaH,P04 and 140mM NaCl, pH 7.4) and once with 0.9% (w/v) NaCl, the cells were collected by centrifugation (175 g, for 5 mm) and the supematant was discarded. The pellets were stored at -80°C.
Isolation of human leucocytes
Leucocytes
were isolated from 15 ml EDTA-anticoagulated blood using lymphopaque (spec. gravity 1.086 g/ ml, 350mOsm). The blood sample (+ 7ml) was layered on 3 ml of lymphopaque using 10 ml LeucoSep tubes and centrifuged at 800g at room temperature for 20 min. The interface containing the leucocytes was collected, diluted with phosphate-buffered saline (PBS; 9.2 mM Na2HP04, 1.3 mM NaH2P04 and 140 mM NaCl, pH 7.4) to a final volume of approximately 12 ml and centrifuged at 800g for 8min. To lyse the erythrocytes, the pellet was resuspended in 5 ml icecold ammonium chloride solution (8.29g/l NH,Cl, l.OOg/l KHCOs and 37.2mg/l EDTA) and kept on ice for 5 min. After the addition of 7ml ice-cold PBS, the solution was centrifuged at 250g at 4°C for 8 min. This step was repeated twice to remove the platelets. The resulting pellet was resuspended in 3 ml PBS and an aliquot was used for cell counting and for a differential count to determine the purity of the leucocyte pellet. The remaining suspension was centrifuged at 11 OOOg at 4°C for 10 s. The supematant was discarded and the pellet was frozen in liquid nitrogen and stored at -80°C until further analysis.
Preparation of jibroblast and leucocyte homogenates
The frozen cell pellets of fibroblasts and leucocytes were suspended in 300~1 35mM potassium phosphate (pH 7.4) and 2.5 mM MgC12 and sonicated three times at 4 W (Vibracell Sonificator, output control 20%) for 10 s with intervals of 30 s under constant cooling in ice-water. After centrifugation (11 OOOg at 4°C for 20 min), the supernatants were removed and saved for further analysis at -80°C. Protein concentrations in the supematants were determined with a copperreduction method using bicinchoninic acid, essentially as described by Smith and associates [25] .
Determination of dihydropyrimidine dehydrogenase activity
The activity of dihydropyrimidine dehydrogenase was determined in a reaction mixture containing 35mM potassium phosphate (pH 7.4), 1 mM dithiothreitol, 2.5 mM MgCls, 250 PM NADPH and 25 PM [14C] thymine. Separation of radiolabelled thymine and the reaction product dihydrothymine was performed isocratically (50 mM NaH2P04 (pH 4.5) at a flow rate of 2 ml/min) by reversed-phase HPLC on a Supelcosil LC-18-S column (250x4.6mm, 5 pm particle size) with on-line detection of radioactivity [26] .
Isolation of RNA and DNA
RNA and DNA were isolated from cultured fibroblasts by the guanidinium thiocyanate method [27] and standard procedures [28] , respectively.
PCR analysis
cDNA synthesis and RT-PCR reactions for amplifying cDNA coding for DPD were carried out essentially as described before [4, 6] .
Four overlapping DPD cDNA fragments were amplified using primer sets as specified in Amplification of the genomic region containing a DPD exon and its flanking sequences was carried out essentially as described before with the primers I1 and I2 [6] . These primers also contained the above-mentioned S-extensions for sequencing purposes. PCR products were separated on 1% agarose gels, visualised with ethidium bromide and purified using a Qiaquickspin PCR purification kit and used for direct sequencing.
Sequence analysis
Sequence analysis was carried out on a Applied Biosystems model 377 automated DNA sequencer using dye-primer method for the DPD cDNA and genomic fragments.
Statistical analysis
The differences between the mean activity of DPD in fibroblasts of controls and obligate heterozygotes were analysed with the two-sample t-test using log transformed data. Similar results were obtained with analysis by the non-parametric Mann-Whitney test of the original data. The level of significance was set a priori at P < 0.05. Analyses were performed with the Statistical Package for the Social Sciences (SPSS Inc. Chicago, Illinois, U.S.A.). Due to the excessive toxicity following the administration of 2700 mg 5-FU in 2 weeks, no further treatment with 5-FU was administered. The treatment with tamoxifen was continued up to 9 April 1992. Up to now, the patient is in good health with no evidence of recurrent cancer.
Clinical evaluation
RESULTS
In
To investigate whether the excessive toxicity following the administration of 5-FU might have been caused by a complete deficiency of DPD, urine was collected on 9 May 1990. However, no abnormalities were observed in the concentration of uracil and thymine.
Activity of DPD in leucocytes and fibroblasts
To investigate whether the severe fluorouracil toxicity in this patient might have been caused by a near-complete deficiency of DPD, we determined the activity of DPD in leucocytes and in cultured fibroblasts established from a skin biopsy. Figure 1 shows that the mean activity of DPD in fibroblasts of controls of 0.89 (kO.56, S.D.) nmol/mg/h is significantly higher (P= 0.002) than that of 0.26 (kO.20, S.D.) nmol/mgih observed in fibroblasts of obligate heterozygotes. In patients suffering from a complete deficiency of DPD, the activity proved to be undetectably low. Surprisingly, the activity of DPD in fibroblasts of the tumour patient (1.1 nmol/mg/h) was within the range of the controls and above the upper limit of the range of DPD activities as observed for the obligate heterozygotes (0.06-0.66 nmol/mgl h). In contrast, in leucocytes the activity of DPD of the tumour patient (3.1 nmol/mg/h) was decreased compared to the mean activity of DPD of controls (9.6nmol f 3.7nmol/ mgh) and was comparable to that observed for obligate heterozygotes (Figure 2) .
RT-PCR analysis of DPD mRNA in culturedfibroblasts
Total RNA isolated from fibroblasts of the tumour patient and controls was subjected to RT-PCR and the coding sequence of the DPD cDNA was fully amplified in four fragments that span 737 bp (fragment A subjects (results not shown). However, the 904 bp fragment C was found together with a smaller sized fragment of 739 bp in the tumour patient, whereas only the normal sized 904 bp fragment was detected in a control subject (Figure 3 , lower panel). For comparison, we also included the analysis of the 904 bp fragment in a Finnish paediatric patient suffering from a DPD deficiency (subject 2) who proved to be homozygous for the smaller sized fragment, whereas his father (subject 1) proved to be heterozygous for the predicted normal-sized fragment and the smaller-sized fragment. Sequence analysis of the PCR fragments showed that the 739 bp fragment originated from the 904 bp fragment by a deletion of 165 bp which proved to be identical to the deletion described previously in two unrelated Dutch patients [4-61. 
Genomic sequence analysis
In order to identify the genomic mutation leading to the observed exon skipping in our patients, two intron specific primers were used for amplification of the complete exon and the upstream and downstream intron sequences [6] . Sequence analysis showed that the tumour patient proved to be heterozygous for a G+A point mutation in the invariant GT splice donor sequence in the intron downstream of the skipped exon (Figure 4(b) ), whereas a normal conserved GT splice donor site was observed in the control (Figure 4(d) ). The paediatric patient suffering from a DPD deficiency proved to be homozygous for the G-+A mutation thereby changing the invariant splice donor site GT into AT (Figure 4(a) ), whereas his father proved to be heterozygous for this type of mutation (Figure 4(c) ).
DISCUSSION
We have provided unambiguous evidence at the molecular level for heterozygosity of a mutated allele of the gene encoding DPD in a tumour patient suffering severe toxicity after administration of 5-FU. Although haematological (leucopenia) and gastrointestinal toxicities (nausea, vomiting, diarrhoea) pared to bolus injections, as a result of the extended infusion of this drug [30-321. Thus, the occurrence of these types of toxicities in our patient might be related to increased 5-FU levels due to a decreased activity of DPD. Furthermore, our patient might be especially prone to the development of 5-FU-associated cardiotoxicity since she is familiar with coronary artery disease [32] . Surprisingly, determination of the activity of DPD in fibroblasts of the S-FU patient showed normal activity of DPD, which was within the range of controls and outside the range of DPD activities as observed for obligate heterozygotes. Although fibroblasts are a very suitable type of tissue to establish a complete deficiency of DPD, the overlapping range in DPD activities between controls and obligate heterozygotes precludes unambiguous detection of heterozygotes. It is now well established that the activity of DPD is generally lower in proliferating (malignant) cells than in resting (differentiated) cells [33-351. Therefore, a conceivable possibility for the large range of DPD activities in fibroblasts might be that the activity of DPD is influenced by the degree of confluency of these fibroblasts. A similar phenomenon has been observed for lysosomal enzyme activities which proved to vary during the various growth phases of human fibroblasts [36] . In that respect, we and others have shown that carrier detection of a deficiency of DPD can be performed by determination of the DPD activity in peripheral mononuclear cells [ 13, 24, 37] . Analysis of the activity of DPD in the leucocytes of the cancer patient demonstrated that the activity of DPD was comparable to that observed in other obligate heterozygotes. Furthermore, the residual activity of DPD in the leucocytes of the cancer patient (32% of the mean DPD activity of leucocytes obtained from healthy donors) is comparable to that observed in other patients suffering from 5-FU toxicities [ 171.
Although the activity of DPD can be detected in a variety of human tissues, it should be borne in mind that the majority of the DPD activity, and therefore the catabolism of 5-FU, is confined to the liver [38, 39] . Lu and associates showed in 2 cancer patients suffering from a partial DPD deficiency that the decreased activity of DPD in peripheral mononuclear cells was paralleled by a decreased activity of DPD in the liver as well [17] . Therefore, they suggested that the activity of DPD in peripheral mononuclear cells could be used as a marker for DPD activity in general. However, Stephan and associates reported a patient with a disease-related liver impairment who suffered from severe toxicities after administration of 5-FU due to a decreased activity of DPD in liver, whereas a normal activity of DPD in lymphocytes was observed [ 181.
The G-A point mutation changes an invariant GT splice donor site into AT which, apparently, leads to skipping of a 165 bp exon immediately upstream of the mutated splice donor site during the splicing of DPD pre-mBNA. As a consequence, a 165 bp fragment encoding the amino acid residues 581-635 of the primary sequence of the DPD protein is lacking in the mature DPD mRNA [4-61. So far, the analysis of 11 patients with a complete deficiency of DPD revealed homozygosity for the G+A point mutation in 6 patients from Denmark, Finland and The Netherlands and heterozygosity for this mutation in 2 patients ([5,6] ; data not shown). The apparent high frequency of this mutation among patients with a complete deficiency of DPD supports the observation that there is some kind of homogeneity for this mutation in Northern Europe [24] .
Although analysis of the DPD activity in 124 healthy subjects [17] and 185 cancer patients [23] did not reveal patients with a complete deficiency of DPD, a number of patients have been found with low activities of DPD experiencing increased toxicities, including death, following 5-FU treatment [ 171. In this respect, the frequency of patients who are heterozygous for a mutated DPD allele has been estimated to be as high as 3% [20-241. Considering the frequent use of 5-FU in the treatment of cancer patients, the severe SFUrelated toxicities in patients with a low activity of DPD and the high frequency of the G-A mutation in DPD deficient patients, analysis of DPD activity in leucocytes and screening for the G-A mutation should be routinely carried out prior to the start of the treatment with 5FU.
Fortunately, the G-A point mutation destroys a unique Mae11 restriction site present in an amplified genomic DNA fragment encompassing the skipped exon and its flanking sequences, allowing the rapid screening of this mutation in patients [6] . The prevalence of this mutation in cancer patients is currently under investigation in our laboratory.
